NASDAQKMDA

georgeclerk Kamada (NASDAQ:KMDA) traded higher on Wednesday after Stifel launched its coverage with a buy recommendation, arguing that the company’s R&D program targeted at a rare lung disorder called AAT deficiency is its “most underappreciated component.“ Stifel’s bullish view comes at a time when the Israeli biotech, which boasts aContinue Reading